Brinzolamide
From Wikipedia, the free encyclopedia
Brinzolamide
|
|
Systematic (IUPAC) name | |
(5R)-5-ethylamino-3-(3-methoxypropyl)- 2,2-dioxo-2λ6,9-dithia- 3-azabicyclo[4.3.0]nona-7,10-diene- 8-sulfonamide |
|
Identifiers | |
CAS number | |
ATC code | S01 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C12H21N3O5S3 |
Mol. mass | 383.51 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | ~60% |
Metabolism | ? |
Half life | 111 days |
Excretion | ? |
Therapeutic considerations | |
Licence data |
, |
Pregnancy cat. |
C(US) |
Legal status | |
Routes | Ophthalmic |
Brinzolamide is a carbonic anhydrase inhibitor.
[edit] References
- Ermis S, Ozturk F, Inan U (2005). "Comparing the effects of travoprost and brinzolamide on intraocular pressure after phacoemulsification.". Eye 19 (3): 303–7. doi: . PMID 15258611.
- Iester M, Altieri M, Michelson G, Vittone P, Traverso C, Calabria G. "Retinal peripapillary blood flow before and after topical brinzolamide.". Ophthalmologica 218 (6): 390–6. doi: . PMID 15564757.
- Kaup M, Plange N, Niegel M, Remky A, Arend O (2004). "Effects of brinzolamide on ocular haemodynamics in healthy volunteers.". Br J Ophthalmol 88 (2): 257–62. doi: . PMID 14736787.
|